Aktuellt
SENASTE
Orphazyme remains committed to pursuing a path to regulatory approval in Europe and the United States, for arimoclomol in NPC despite a Complete Response Letter from FDA. It could prove to be difficult as a likely outcome would be request for more clinical data which would call for financing combined with the fact that it is difficult to find patients for a large study.
LÄS MER
